OR WAIT null SECS
Shimadzu’s new ultra-high performance liquid chromatography system is designed to solve common problems in biopharma analysis.
Shimadzu launched its new Nexera XS inert, a bioinert and biocompatible ultra-high performance liquid chromatograph (UHPLC), in July 2022. The system is designed to resolve the most common problems in biopharmaceutical analysis, such as the adsorption of target molecules to metal surfaces and mobile-phase corrosion caused by high salt content and extreme pH conditions.
The Nexera XS inert UHPLC resulted from cooperative research done with Yasushi Ishihama, a professor at the Graduate School of Pharmaceutical Sciences at Kyoto University in Japan under the Japan Science and Technology Agency’s Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) project from 2017 to 2020. The system features a metal-free sample flow path, which prevents unwanted interaction with biopolymers that are prone to adsorption onto exposed metal sites. Through this mechanism, the Nexera XS inert results in reduced sample loss and excellent peak shape for generating reproducible, high-sensitivity and high-quality reliable data, according to a July 19, 2022 company press release.
Furthermore, all wetted surfaces have been prepared from corrosion-resistant materials, which renders them stable against mobile-phase solvents that contain high concentrations of salts or acids. Nexera XS inert is particularly well-suited for analyzing biopharmaceutical molecules, such as antibodies, peptides, and nucleic acid drugs.
The new system offers the same analytical intelligence features as the other products in the Nexera series as well as the following features: